Total Payments
$1.0M
2024 Payments
$91,741
Companies
72
Transactions
341
Payment Breakdown by Category
Consulting$935,681 (91.3%)
Travel$39,224 (3.8%)
Research$32,434 (3.2%)
Other$15,000 (1.5%)
Food & Beverage$2,937 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $935,681 | 242 | 91.3% |
| Travel and Lodging | $39,224 | 49 | 3.8% |
| Unspecified | $32,434 | 15 | 3.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,000 | 10 | 1.5% |
| Food and Beverage | $2,937 | 25 | 0.3% |
Payments by Type
General
$992,842
326 transactions
Research
$32,434
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals, Ltd | $156,028 | 31 | $0 (2020) |
| PFIZER INC. | $111,339 | 35 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $104,947 | 9 | $0 (2023) |
| Janssen Research & Development, LLC | $63,442 | 23 | $0 (2024) |
| Mirum Pharmaceuticals, Inc. | $50,213 | 2 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $31,848 | 13 | $0 (2024) |
| Biogen, Inc. | $29,954 | 10 | $0 (2024) |
| Sarepta Therapeutics, Inc. | $27,645 | 15 | $0 (2024) |
| AbbVie Inc. | $24,419 | 15 | $0 (2023) |
| GW Research Limited | $24,400 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $91,741 | 25 | Mirum Pharmaceuticals, Inc. ($35,100) |
| 2023 | $126,801 | 38 | INTERCEPT PHARMACEUTICALS, INC. ($31,233) |
| 2022 | $95,952 | 33 | Janssen Research & Development, LLC ($18,688) |
| 2021 | $99,179 | 28 | Biohaven Pharmaceuticals, Inc. ($19,963) |
| 2020 | $123,193 | 29 | Intercept Pharmaceuticals, Inc. ($48,000) |
| 2019 | $158,498 | 66 | Actelion Pharmaceuticals, Ltd ($44,625) |
| 2018 | $130,389 | 45 | Actelion Pharmaceuticals, Ltd ($44,603) |
| 2017 | $199,523 | 77 | Actelion Pharmaceuticals, Ltd ($62,574) |
All Payment Transactions
341 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 11/18/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,408.75 | General |
| 08/27/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,080.00 | General |
| 08/02/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,528.00 | General |
| 06/24/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| 06/24/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| 06/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,762.50 | General |
| 06/01/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $35,100.00 | General |
| Category: Alagille syndrome | ||||||
| 05/13/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| 05/13/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 05/09/2024 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| 04/26/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $4,044.00 | General |
| 04/16/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,787.50 | General |
| 04/16/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Consulting Fee | Cash or cash equivalent | $960.00 | General |
| Category: NEUROLOGY | ||||||
| 04/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,408.75 | General |
| 03/27/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,462.50 | General |
| 03/06/2024 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,575.00 | General |
| 01/20/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $11,651.64 | General |
| 01/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 01/18/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: NEUROLOGY | ||||||
| 01/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 01/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,462.50 | General |
| 01/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) | Biogen, Inc. | $21,684 | 5 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $5,950 | 5 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $1,300 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA | Allergan Inc. | $1,000 | 1 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $1,000 | 2 |
About Dr. Paul Watkins, MD
Dr. Paul Watkins, MD is a Gastroenterology healthcare provider based in Chapel Hill, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386705366.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Watkins, MD has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $91,741 received in 2024. These payments were reported across 341 transactions from 72 companies. The most common payment nature is "Consulting Fee" ($935,681).
Ad
Practice Information
- Specialty Gastroenterology
- Location Chapel Hill, NC
- Active Since 12/13/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1386705366
Products in Payments
- OPSUMIT MACITENTAN (Drug) $96,699
- Livmarli (Drug) $50,213
- OPSUMIT (Drug) $30,125
- Epidiolex (Drug) $22,500
- TECFIDERA (Drug) $21,684
- Ella (Drug) $19,247
- XELJANZ (Drug) $15,250
- KISQALI (Drug) $11,350
- EPIDIOLEX (Drug) $11,068
- Exondys 51 (Drug) $10,695
- Turalio (Drug) $9,450
- OCALIVA (Drug) $6,500
- Cimzia (Drug) $5,500
- SKYRIZI (Biological) $4,875
- OCA (Drug) $4,000
- INVOKANA (Drug) $3,875
- GIVLAARI (Drug) $3,250
- TIBSOVO (Drug) $3,125
- BREMELANOTIDE (Drug) $3,000
- Lonsurf (Drug) $2,500
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Chapel Hill
Evan Dellon, M.d., M.p.h, M.D., M.P.H
Gastroenterology — Payments: $668,290
Gastroenterology $668,290
Dr. Hans Herfarth, Md, MD
Gastroenterology — Payments: $422,697
Gastroenterology $422,697
Dr. Nicholas Shaheen, Md, MD
Gastroenterology — Payments: $172,004
Gastroenterology $172,004
Dr. Christine Hunt, M.d, M.D
Gastroenterology — Payments: $168,134
Gastroenterology $168,134
Dr. Ryan Sartor, Md, MD
Gastroenterology — Payments: $103,709
Gastroenterology $103,709
Dr. Spencer Dorn, M.d, M.D
Gastroenterology — Payments: $72,462
Gastroenterology $72,462